Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Adaptimmune Therapeutics PLC

Get SEC filing alerts via email and in your feed for Adaptimmune Therapeutics PLC

ADAP

Adaptimmune Therapeutics PLC

About Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics plc is a biopharmaceutical company specializing in engineered autologous T-cell therapies targeting solid tumor cancers. Its core products, including TECELRA and lete-cel, focus on treating synovial sarcoma and myxoid liposarcoma by modifying patients’ T-cells to recognize cancer-specific antigens. The company leverages proprietary T-cell receptor (TCR) and TRuC platforms, serving oncology patients through personalized immunotherapies with a commercial and clinical-stage business model.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Adaptimmune Therapeutics PLC

1
1
Adaptimmune Therapeutics PLC Adaptimmune Reports 89% Revenue Decline and $30.3 Million Net Loss in Latest Quarter

Via official filing (AI summary) | 10 months ago | 0 comments

2
1
Adaptimmune Therapeutics PLC Adaptimmune Therapeutics Reports $178M Revenue Growth and Restructuring Efforts

Via official filing (AI summary) | about 1 year ago | 0 comments

3
1
Adaptimmune Therapeutics PLC Adaptimmune Reports Significant Revenue Growth and Improved Financials in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments